Atara Biotherapeutics Inc (ATRA)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Atara Biotherapeutics Inc chart...

About the Company

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have

CEO

Pascal Touchon

Exchange

NASDAQ

Website

http://www.atarabio.com/

$24M

Total Revenue

502

Employees

$71M

Market Capitalization

-0.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ATRA News

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

10h ago, source:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023

on MSN ago, source:

ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for ...

Atara Biotherapeutics: Q4 Earnings Snapshot

10h ago, source:

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $60.5 million in its fourth quarter. The Thousand Oaks, California-based ...

Analysts Say You Should Hold Your Position In Atara Biotherapeutics Inc (NASDAQ: ATRA)

10d ago, source:

Atara Biotherapeutics Inc (NASDAQ:ATRA) traded at $0.60 at close of the session on Monday, March 18, made a downward move of -4.06% on its previous day’s price.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)

9d ago, source:

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fusion Pharmaceuticals (FUSN – Research ...

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

9d ago, source: Zacks.com on MSN

The price trend for Arcutis Biotherapeutics, Inc. (ARQT) has been bearish lately and the stock has lost 6.5% over the past two weeks. However, the formation of a hammer chart pattern in its last ...

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

10d ago, source: Business Insider

Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Atara Biotherapeutics ... Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. I-MAB has an analyst ...

Stock Indexes Consolidate Below Thursday’s Record Highs

6d ago, source: Barchart on MSN

The S&P 500 Index ( $SPX) ( SPY) this morning is down -0.11%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down -0.14%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down -0.25%.

Stocks Consolidate Below This Week’s Record Highs

6d ago, source: Barchart on MSN

FedEx ( FDX) is up more than +7% to lead gainers in the S&P 500 after reporting Q3 adjusted EPS of $3.86, stronger than the consensus of $3.46 billion, and announcing a $5 billion stock buyback plan.

Atara Biotherapeutics: Q4 Earnings Insights

13h ago, source: Benzinga.com

Atara Biotherapeutics ATRA reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM. Here's what investors need to know about the announcement. Atara Biotherapeutics missed estimated ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...